优化EGFR-TKI治疗选择,助力NSCLC长生存获益( 三 )


[6].https://wclc2018.iaslc.org/abstracts-scholarships/abstracts-2/.
[7].RamalingamSS,VansteenkisteJ,PlanchardD,etal.OverallSurvivalwithOsimertinibinUntreated,EGFR-MutatedAdvancedNSCLC.NEnglJMed.2020Jan2;382(1):41-50.
[8].LeighlNB,KarasevaN,NakagawaK,etal.Patient-reportedoutcomesfromFLAURA:OsimertinibversuserlotiniborgefitinibinpatientswithEGFR-mutatedadvancednon-small-celllungcancer.EurJCancer.2020;125:49-57.
[9].1295P-OsimertinibvscomparatorEGFR-TKIasfirst-linetreatmentforEGFRmutated(EGFRm)advancedNSCLC:FLAURAChinastudyoverallsurvival(OS).2020ESMOAbstacts:1295P.
*截至2021.09.08
审批编号CN-82960过期日期2021-12-7
*此文仅用于向医学人士提供科学信息 , 不代表本平台观点
优化EGFR-TKI治疗选择,助力NSCLC长生存获益
文章图片